Institute of Medicine report called the pattern of higher rates of disease and shorter lives “the U.S. health disadvantage,” and said it was responsible for dragging the country to the bottom in terms of life expectancy over the past 30 years. Continue reading →
Part I. America’s commercially profitable healthcare system is wasteful, inefficient and exceedingly harmful. Medical interventions are the third Leading cause of death.
“Prescription drug therapy stands as one of the most significant perils to health resulting from human activity.” What’s the FDA doing to stem the tide of this preventable epidemic? Continue reading →
Three new studies–one,, a pharmaco-genetic study, is groundbreaking–confirm that widely prescribed psychotropic drugs that pose serious risks of harm, offer no therapeutic benefit.
Why the tragic case of Dna Markingson and the culpability of the University of Minnesota won’t go away… Continue reading →
"Prescription Drugs Associated with Reports of Violence Towards Others, " identifies 31 drugs linked to 1,527 acts of violence… Continue reading →
The catalyst for Dr. Elliott’s article was the tragic case of Dan Markingson, a 26-year old who committed suicide in May 2004, while enrolled in the CAFE trial, prescribed Seroquel. This case encapsulates the tragic consequences of a broken system which is not designed to detect the hazards for human subjects posed by market-driven research. Continue reading →
Two news reports: Alaska Supreme Court decision and a JAMA report confirms that risk of violence among schizophrenia patients "was mostly confined to patients with substance abuse comorbidity." Continue reading →
Did Zoloft make him do it? FDA Zoloft data Tue, 8 Feb 2005 At issue beyond a Charlsteon, SC court, is whether Christopher Pittman – who was 12 years old and under the influence of Zoloft, a powerful psychotropic drug, when he . . . Continue reading →
Forbes: Judgment Day for the FDA, Pfizer Wed, 9 Feb 2005 On Feb. 16-18 COX-2 Inhibitor Safety Issues will be the focus of an FDA Advisory Committee and (simultaneously) the European Medicines Agency (EMA). The entire drug industry will be watching with . . . Continue reading →